Form 4: Microbot Medical CFO Rachel Vaknin Reports Stock Option Grant and Vesting

Rachel Vaknin, CFO of Microbot Medical Inc., reports the acquisition of stock options and the vesting of performance-based options.

Summary

• On February 7, 2025, Rachel Vaknin, the Chief Financial Officer of Microbot Medical Inc., filed a Form 4.
• The report details the acquisition of 48,125 stock options with an exercise price of $2.04 on February 5, 2025.
• These options vest starting August 5, 2025, with 25% vesting initially and the remaining 75% vesting quarterly over the next 30 months.
• Additionally, 4,375 performance-based options with an exercise price of $1.25, granted on February 26, 2024, vested on February 5, 2025, after the Compensation Committee confirmed the achievement of milestones.
• Following these transactions, Vaknin directly owns 48,125 stock options with an exercise price of $2.04 and 4,375 stock options with an exercise price of $1.25.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. It doesn't contain information that would significantly sway investor sentiment positively or negatively.

Positives

• The vesting of performance-based options suggests that the company is achieving its milestones.
• The grant of new stock options to the CFO aligns her interests with those of the shareholders.

Industry Context

This filing is a routine disclosure related to insider transactions and is typical for publicly traded companies. It provides transparency regarding the compensation and ownership structure of the company's executives.

Stakeholder Impact

• Shareholders may view the vesting of performance-based options as a positive sign, indicating that the company is achieving its goals.
• Employees may be motivated by the fact that executives are receiving stock options, aligning their interests with the company's success.

Key Dates